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Aims Oral glucose-lowering medications are associated with excess risk of heart failure (HF). Given the absence of compara-
tive data among drug classes, we performed a retrospective study in 32 Health Services of 16 Italian regions accounting




We extracted data on patients with type 2 diabetes who initiated treatment with DPP-4i, thiazolidinediones, or sulpho-
nylureas alone or in combination with metformin during an accrual time of 2 years. The endpoint was hospitalization for
HF (HHF) occurring after the first 6 months of therapy, and the observation was extended for up to 4 years. A total of
127 555 patients were included, of whom 14.3% were on DPP-4i, 72.5% on sulphonylurea, 13.2% on thiazolidinediones,
with average 70.7% being on metformin as combination therapy. Patients in the three groups differed significantly for
baseline characteristics: age, sex, Charlson index, concurrent medications, and previous cardiovascular events. During
an average 2.6-year follow-up, after adjusting for measured confounders, use of DPP-4i was associated with a reduced
risk of HHF compared with sulphonylureas [hazard ratio (HR) 0.78; 95% confidence interval (CI) 0.62–0.97;
P ¼ 0.026]. After propensity matching, the analysis was restricted to 39 465 patients, and the use of DPP-4i was still
associated with a lower risk of HHF (HR 0.70; 95% CI 0.52–0.94; P ¼ 0.018).
Conclusion In a very large observational study, the use of DPP-4i was associated with a reduced risk of HHF when compared with
sulphonylureas.
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Introduction
Type 2 diabetes (T2D) is associated with excess cardiovascular dis-
ease, including a marked increase in the risk of heart failure (HF).1
Interest in the cardiovascular effects of glucose-lowering medica-
tions is extremely high, and the number of drug categories for the
treatment of T2D is rapidly expanding. According to the joint
EASD/ADA position statement on the management of hypergly-
caemia in T2D, ‘comprehensive cardiovascular risk reduction
must be a focus of therapy’.2 Unfortunately, availability of robust
data on solid cardiovascular endpoints in patients treated with
different glucose-lowering regimens is limited. Incretin-based ther-
apies, including GLP-1 receptor agonists and DPP-4 inhibitors
(DPP-4i), have pleiotropic cardiovascular effects, demonstrated ex-
perimentally and clinically, which may translate into protection from
vascular events.3 However, recent data have raised concerns about
the risk of HF associated with the use of DPP-4i. In the Saxagliptin
Assessment of Vascular Outcomes Recorded in Patients with Dia-
betes Mellitus (SAVOR) study, therapy with the DPP-4i saxagliptin
vs. placebo over a median of 2.1 years was associated with a 27% ex-
cess hospitalization for HF (HHF).4 In contrast, the EXAMINE trial,
conducted in patients with recent acute coronary syndrome, showed
that the DPP-4i alogliptin did not significantly increase the risk of HHF
compared with placebo.5 Subsequently, results from observational
studies on DPP-4i therapy reported a neutral effect on HHF,6,7 or ex-
cess risk of HHF,8 or excess HHF risk only in patients with a previous
HF history.9 Results from meta-analyses of randomized trials also
suggested that DPP-4i is associated with an increased HF risk,10–12
although most of this conclusion is driven by the SAVOR trial.
In this study, making use of a registry including about 30% of the
Italian population, we performed a retrospective analysis to assess
the association between use of oral glucose-lowering medications
and subsequent HHF. We specifically assessed the risk conferred
by DPP-4i compared with sulphonylureas, as still being the most
widely used oral medications for T2D in Italy, and with thiazolidine-




This retrospective study used data from the Nationwide OsMed
Health-DB Database. This database, participated by 35 Italian Local
Health Units (LHUs), includes about 18 million subjects (30% of the Ital-
ian population), with a uniform distribution in North (28.7%), Center
(33.7%), and South (29.8%) of Italy and a historical series from 2009.
The mean age (43.5 years) and the percentage of males (48.5%) in indi-
viduals included in the database are in accordance with national data.
The Italian Medicines Agency (AIFA—Agenzia Italiana del Farmaco) is
the national competent authority responsible for regulation of medi-
cine’s use in Italy. Inside AIFA, the OsMed monitors nationwide the
use of medicines in Italy, and it performs analyses on patients’ level
data prospectively by the technical support of CliCon. Clicon was dele-
gated by AIFA for data warehousing and data mining activities of infor-
mation voluntarily provided by LHUs and stored in their own local
administrative databases. To comply with privacy legislation, patient
ID code was anonymized by LHUs. Using this database, OsMed reports
on medication use in Italy are published yearly by AIFA with the
following objectives: (i) to describe drug consumption nationwide, (ii)
to examine changes in drug use over time, (iii) to benchmark drug
consumption across different Italian regions, and (iv) to evaluate
appropriate use of drugs and adherence with treatment.
For this study, anonymous patient records were retrieved from mul-
tiple administrative health service databases, including peripheral and
centralized pharmaceutical services, hospital discharge charts, disease-
specific economic exemption, and health services provided by LHUs
and hospitals. For each individual, such data were integrated to yield a
chronologic and analytic profile. Accrual time was set between 1 January
2010 and 31 December 2012. We included all patients with T2D who
were prescribed for the first time and at least once a DPP-4i (ATC
classes A10BH/A10BD07/A10BD08), a sulphonylurea (ATC classes
A10BB/A10BD01/A10BD02), or a glitazone (ATC classes A10BB/
A10BD01/A10BD02), alone or in combination with metformin. No
other combinations were allowed, but patients could have been previ-
ously treated with different oral glucose-lowering drugs in the 12
months preceding the index date. The date of first prescription was
set as the index date, from which the observation of each patient
started. The endpoint was defined as a hospital discharge event with a
primary diagnosis of HF, with an ICD-9 code 428, up to the end of the
observation period, at 31 December 2013 or the death, whichever
occurred earlier. This information was retrieved only from hospital dis-
charge charts, which are uniformly coded and standardized in all Italian
LHUs and hospitals, are compiled by the physician(s) directly in charge
of the patients, and are individually validated by hospitals against detailed
clinical-instrumental data, as they determine reimbursement from the
National Health System. In addition, to limit the chance of misclassifica-
tion in the primary analysis, the endpoint was met only when HF was the
primary diagnosis in discharge charts, and not when it was a concomi-
tant diagnosis (e.g. HF in patients with a primary diagnosis of acute kid-
ney disease or acute respiratory failure), because the interplay between
glucose-lowering medications and secondary HF may be indirect and
more difficult to infer. Exposure time was calculated from prescriptions
and access to the pharmaceutical services to indicate total treatment
duration, whereas time to event was the time elapsed from index data
and date of the event (coded date of the hospital discharge).
Exclusion criteria for the primary analysis were: a previous HHF (hos-
pital discharge ICD-9 code 428) during the 12 months before the index
date; use of insulin during the 12 months before the index date or during
the observation period; and observation time shorter than 6 months
after the index date, to ensure a minimum interval for adherence assess-
ment (the use of short intervals to assess adherence does not reflect
long-term behaviours)13 and to avoid reverse causality. Several subse-
quent sensitivity analyses were then performed including: patients
with a previous HHF episode; patients censored in the first 6 months;
and patients with HHF episodes in secondary diagnosis. For all patients,
we collected the following data, recorded in the 12 months before the
index date: age, sex, Charlson index, previous hospitalization for cardio-
vascular causes (ICD-9 codes 410–414 for myocardial infarction, ICD-9
430–438 for stroke, ICD-9 440–442 for peripheral arterial disease, and
ICD-9 401–405 for other cardiovascular diseases), previous glucose-
lowering medications use, ongoing medications for hypertension
(ATC classes C02, C03, C07–09), dyslipidaemia (ATC class C10),
chronic obstructive pulmonary disease (ATC class R03), and anti-
inflammatory (ATC class M10) and anti-platelet medications (ATC class
B01). Adherence to glucose-lowering medications was defined using the
medication possession ratio (MPR), a method used in prior studies to
quantify medication adherence.14,15 The MPR was estimated by calculat-
ing the proportion of pill-days available from filled prescriptions of the
oral glucose-lowering medications during the interval from the index
date until a first HHF, death, or 31 December 2013, whichever occurred
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first. In the case of combination with metformin, the average of the
MPRs for each class of drugs was calculated. Days when patients
were in an institutionalized care setting, such as hospitals, were excluded
from the MPR calculation. We defined ‘non-adherence’ as an
MPR , 80%.16,17
Statistical analysis
Data are expressed as mean+ standard deviation or as percentage
where appropriate. Comparisons among groups were performed using
analysis of variance (ANOVA) and Pearson’s x2 test for continuous and
categorical data, respectively. The post hoc Bonferroni correction was
used to account for multiple testing. The Cox proportional hazard re-
gression analysis was used to describe the associations between
glucose-lowering medication regimen and the endpoint. The other
covariates in the model were: age, sex, the use of certain medications
(yes/no) (drugs for hypertension, dyslipidaemia, chronic obstructive pul-
monary disease, non-steroidal anti-inflammatory drugs, and anti-platelet
medications), the presence of previous hospitalizations (yes/no), the
Charlson index level grouped into three categories (index score ¼ 1;
between 2 and 3; and ≥4), previous oral glucose-lowering medications
(yes/no), the presence of a co-treatment with metformin (yes/no), and
adherence level categorized on the basis of the MPR and grouped into
two categories, i.e. MPR , 80 and MPR ≥ 80%. Patients without study
outcomes were considered as censored. The proportional hazards
assumption was not violated.
In addition to the main analysis, as in the observational studies, treat-
ment selection is often influenced by subject characteristics; in order to
address the issues of confounding by indication, we used a propensity
score-matching analysis to balance the different glucose-lowering treat-
ment groups on the possible baseline confounders (1 : 1 : 1 match).18
A multinomial logistic model was performed, and the probability of
receiving each treatment category given the observed covariates was es-
timated. All the variables listed in Table 1 were included in the model,
regardless of statistical significance.19 After fitting the model, patients
were ranked by their estimated propensity score and grouped within
quintiles.20 Quintiles are commonly used for adjustment, as they are
expected to remove 90% of the confounding. However, the smaller
the strata are, the better they will balance the covariates and the
more confounding they will remove.21 Thus, also deciles of the propen-
sity score were created. The balance of the confounders was assessed
using the standardized difference.21 Next, a pairwise random sampling ap-
proach was used. Within each stratum, first, equal sample sizes in the
DPP-4i and glitazone groups were selected; then, equal sample sizes
were randomly chosen among the DPP-4 sample previously selected
and the sulphonylurea group, obtaining the same sample size among
the three groups.22 We used Kaplan–Meier curve techniques to calculate
cumulative survival probability of HHF among the three propensity score-
matched samples.23 Unadjusted survival group comparisons were made
with a log-rank test. An additional Cox proportional hazard regression
analysis was performed to describe the associations among glucose-
lowering medication regimen, adherence level, and the endpoint. Statistical
significance was accepted at P , 0.05, and Stata software version 12.1
(StataCorp LP, College Station, TX, USA) was used.
Results
Baseline characteristics
A total of 127 555 patients were included in the analysis. During the
observation period, 14.3% were treated with a DPP-4i, 72.5% with a
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Clinical characteristics of the entire study cohort
Characteristics All DPP-4i Sulphonylureas TZD P-value
Number (%) 127 555 (100.0) 18 294 (14.3) 92 463 (72.5) 16 798 (13.2)
Age, mean+ SD 67.0+13.4 62.3+11.6* 68.5+13.5 63.5+13.2*** ,0.001
Sex, % male 51.9 56.3* 50.5** 54.6*** ,0.001
Charlson index
1 72.6 58.4* 76.8** 64.7*** ,0.001
2–3 24.1 37.7* 20.1** 31.6***
≥4 3.3 3.9* 3.1** 3.7***
Previous cardiovascular event (%) 4.5 5.3* 4.4 4.6*** ,0.001
Previous glucose-lowering medications (%) 35.9 77.8* 24.1** 54.8*** ,0.001
Other medications
Diuretics (%) 1.1 0.7* 1.3** 0.9 ,0.001
Beta-blockers (%) 2.2 3.0* 2.1 2.3*** ,0.001
Calcium channel blockers (%) 1.5 1.3* 1.6** 1.3 ,0.001
RAS blockers (%) 15.3 19.9* 13.8** 18.5*** ,0.001
Combination of blood-pressure-lowering drugs (%) 31.8 37.3* 30.6** 32.2*** ,0.001
Lipid lowering (%) 26.3 44.2* 21.5** 33.2*** ,0.001
Anti-inflammatory (%) 20.0 19.5* 19.7** 22.1*** ,0.001
Anti-chronic obstructive pulmonary disease (%) 7.5 6.9* 7.6 7.5 0.004
Anti-platelet (%) 26.2 34.0* 24.3** 27.9*** ,0.001
ANOVA P-values are shown: after post hoc Bonferroni correction.
*P , 0.05 in the comparison between DPP-4i and sulphonylureas.
**P , 0.05 in the comparison between sulphonylureas and glitazones (TZD).
***P , 0.05 in the comparison between DPP-4i and TZD.
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sulphonylurea, and 13.2% with a glitazone (which was pioglitazone
in 98.2% of the cases). Overall, 70.7% of the patients were
co-treated with metformin (86.4% for DPP-4i, 79.5% for glitazones,
and 65.9% for sulphonylureas). Upon ANOVA or Pearson’s x2 test,
all clinical characteristics differed according to the ongoing glucose-
lowering regimen (Table 1).
Hospitalization for heart failure risk
During the observation period (mean follow-up of 2.6 years), a total
of 1778 HF hospital discharge events were recorded, occurring in
1319 patients (equal to an average 1.35 episodes/patient). Inci-
dences of the outcome in patients divided according to the ongoing
glucose-lowering regimen are reported in Table 2.
In a Cox proportional hazard regression model adjusted for all
clinical variables collected at baseline, the HHF risk was significantly
lower in patients treated with a DPP-4i [hazard ratio (HR) 0.78
(0.62–0.97); P ¼ 0.026] and lower, but not significantly, in patients
treated with a glitazone [HR 0.89 (0.74–1.06); P ¼ 0.188] than that
in patients treated with a sulphonylurea (Table 3). With DPP-4i as
reference, the HRs were 1.29 (1.03–1.61) for sulphonylureas
(P ¼ 0.026) and 1.14 (0.88–1.48) for glitazones (P ¼ 0.334),
respectively. Overall, the HHF resulted in death in 17.3% of the
patients. There were no differences in the incidence of fatal HHF
among patients treated with DPP-4i, sulphonylureas, and glitazones
(Table 2).
Given the multiple statistically significant and clinically relevant
differences among the groups of patients treated with DPP-4i, glita-
zones, and sulphonylureas (Table 1), a propensity score matching
was performed. Once the logistic model was fitted, patients were
ranked, divided into quintiles, and the balance of confounders was
checked, but it was not good enough. The data were then divided
into deciles of the propensity score, and the balance of confounders
was re-checked (Figure 1). We obtained a better balance using 10
strata rather than 5, and the differences were much smaller than
before (all ,0.1 SD). After performing the random selection within
strata, the number of patients included in the analysis was reduced
to 39 465 (Supplementary material online, Table S1). In this matched
cohort, DPP-4i, glitazones, and sulphonylureas were associated with
metformin on average on 80.6% (83.4% for DPP-4i, 83.3% for glita-
zones, and 75.0%, for sulphonylureas). Incidences of the outcome in
this subcohort divided according to the ongoing glucose-lowering
regimen are reported in Table 2 (lower part). Figure 2 shows the
Kaplan–Meier curves of HHF-free survival among the propensity
score-matched groups. The crude HHF incidence was lowest in
patients treated with DPP-4i and highest in patients treated with
sulphonylureas (P ¼ 0.014). In the Cox proportional hazard regres-
sion analysis, the risk of HF remained significantly lower in patients
treated with a DPP-4i [HR 0.70 (0.52–0.94); P ¼ 0.018] than that
in patients treated with a sulphonylurea, even after propensity
matching (Table 3). Using DPP-4i as reference, the HRs were 1.42
(1.06–1.91) for sulphonylureas (P ¼ 0.018) and 1.16 (0.86–1.58)
for glitazones (P ¼ 0.331), respectively. Still, no differences among
groups in fatal HHF were detected (Table 2).
Sensitivity analysis
Among the 2609 patients excluded from the primary analysis for
having less than 6 months of follow-up, 508 (19.5%) experienced
a HHF. Using sulphonylureas as reference, the HRs for HHF were
1.46 [95% confidence interval (CI) 1.09–1.96; P ¼ 0.011] for
DPP-4i and 0.89 (95% CI 0.65–1.22; P ¼ 0.457) for glitazones.
When these subjects were included in the primary analysis, for a to-
tal of 130 164 patients, the HRs for HHF were 0.92 (95% CI 0.77–
1.09; P ¼ 0.318) for DPP-4i and 0.86 (95% CI 0.74–1.01; P ¼ 0.062)
for glitazones. Violation of proportional hazard assumption in this
model lends support to the exclusion of patients with ,6 months
of follow-up.
Including patients who had experienced a HF episode during the
12 months before the index date, using the sulphonylurea as
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Incidences of the endpoint (events of hospitalization discharge with a diagnosis of HF) in patients before (whole
cohort) and after propensity matching
Before propensity matching DPP-4i Sulphonylureas TZD
Patient number 18 294 92 463 16 798
Patients with events, n (%) 96 (0.5) 1085 (1.2) 138 (0.8)
Total events, n 131 1465 182
Patients with fatal events, n (%) 27 (0.2) 176 (0.2) 25 (0.1)
Mean exposure time+ SD 2.2+0.8 2.6+0.8 2.6+0.8
Crude event rate (per 1000 person-years) 2.4 4.5 3.1
After propensity matching
Patient number 13 155 13 155 13 155
Patients with events, n (%) 71 (0.5) 128 (1.0) 103 (0.8)
Total events, n 93 183 127
Patients with fatal events, n (%) 19 (0.1) 22 (0.2) 19 (0.1)
Mean exposure time+ SD 2.2+0.8 2.6+0.8 2.6+0.8
Crude event rate (per 1000 person-years) 2.4 3.8 3.0
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reference, the HRs for HHF were 0.63 (95% CI 0.34–1.16;
P ¼ 0.140) for DPP-4i and 1.31 (95% CI 0.80–2.16; P ¼ 0.282) for
glitazones.
When considering hospitalizations with both primary and sec-
ondary HF diagnoses, a total of 3229 HF hospital discharge events
were recorded, occurring in 2210 of the 127 555 patients, 60% of
whom had already been included in the primary analysis. Using sul-
phonylureas as reference, the HRs for HHF were 0.75 (95% CI
0.63–0.89; P ¼ 0.001) for DPP-4i and 0.93 (95% CI 0.81–1.06;
P ¼ 0.277) for glitazones (Table 4). After the propensity score
matching, using sulphonylureas as reference, the HRs for HHF
were 0.64 (95% CI 0.51–0.81; P , 0.001) for DPP-4i and 0.78
(95% CI 0.63–0.95; P ¼ 0.014) for glitazones.
Discussion
In this retrospective analysis of 127 555 unmatched patients with
T2D, extracted from a population of 18 million individuals, we
show that the risk of HHF in patients with T2D taking DPP-4i
over a period of 2.6 years was significantly lower than that in patients
taking sulphonylureas. The finding was confirmed when the analysis
was restricted to 39 465 propensity-matched patients with T2D.
This resulted from a decrease of non-fatal HHF in DPP-4i-treated
patients, as the rate of fatal HHF was not different among treatment
groups.
Almost all oral glucose-lowering medications may increase the
risk of HF.24 The excess cardiovascular risk of glitazones prompted
regulatory agencies to require post-approval safety studies for all
new products approved for the treatment of T2D.25 Given that
this guideline has been implemented only recently, observational
studies can bridge this gap of information, while awaiting results of
cardiovascular safety studies.
Incretin-based therapies have pleiotropic effects that may reduce
cardiovascular risk.26 However, there are several reasons whereby
pre-clinical findings and clinical studies on surrogate endpoints may
not translate into a protection from hard endpoints. DPP-4i can
affect vascular function via GLP-1-dependent and -independent ac-
tions.3 Although GLP-1-dependent effects are common to GLP-1
receptor agonists, the DPP-4 enzyme inactivates several substrates
different from incretin hormones (including cytokines, chemokines,
and neurohormones),27 many of which can exert favourable, but un-
predictable, vascular effects in the clinical setting and in the long run.
Unexpectedly, in the SAVOR trial, conducted on 16 492 patients
with T2D and a history of, or at risk for, cardiovascular events, who
were randomized to saxagliptin or placebo, an excess 27% HHF was
detected in the saxagliptin group over a mean follow-up of 2.1
years.4 A subsequent re-analysis of this study reported that excess
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Results of the Cox proportional hazard multiple regression analysis in the whole study population
Variable Before propensity matching After propensity matching
HR (95% CI) P-value HR (95% CI) P-value
Age 1.066 (1.060–1.072) ,0.001 – –
Sex male 1.301 (1.165–1.454) ,0.001 – –
Charlson index
1 (reference) 1.000
2–3 1.301 (1.132–1.495) ,0.001
≥4 1.580 (1.250–1.998) ,0.001 – –
Previous cardiovascular event 1.950 (1.651–2.304) ,0.001 – –
Previous glucose-lowering medications 1.235 (1.061–1.437) 0.007
Glucose-lowering medications
Sulphonylureas (reference) 1.000 1.000
Glitazones 0.885 (0.738–1.061) 0.188 0.816 (0.629–1.059) 0.126
DPP-4 inhibitors 0.777 (0.623–0.970) 0.026 0.702 (0.524–0.940) 0.018
Combination with metformin 1.025 (0.902–1.165) 0.705 – –
Adherence to therapy 0.492 (0.437–0.555) ,0.001 0.458 (0.364–0.576) ,0.001
Other medications
Diuretics 1.706 (1.215–2.395) 0.002 – –
Beta-blocking agents 0.690 (0.410–1.160) 0.162
Calcium channel blockers 1.252 (0.850–1.844) 0.256
Agents acting on the renin–angiotensin system 0.770 (0.624–0.950) 0.015
Combination of blood-pressure-lowering drugs 1.519 (1.311–1.761) ,0.001
Lipid-lowering 0.907 (0.796–1.034) 0.144 – –
Anti-inflammatory 0.716 (0.621–0.827) ,0.001 – –
Anti-chronic obstructive pulmonary disease 1.259 (1.074–1.477) 0.005 – –
Anti-platelet 1.667 (1.461–1.902) ,0.001 – –
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HHF risk decreased after the first 6 months of randomization and
was highest among patients with elevated levels of natriuretic
peptides, previous HF, or chronic kidney disease.28
Primed by these data, several observational studies reported
conflicting results on the association between DPP-4i and HF.
In a population-based study in Taiwan, including 8288 matched
pairs of patients, treatment with sitagliptin was associated with
a significant 21% increase in HHF, with no change in all-cause
mortality.8 In a nested case – control study conducted on 10
073 Danish patients with T2D, DPP-4i had a neutral effect on
all cardiovascular outcomes, including HF.7 In a population-
based retrospective cohort study including 7620 patients with
T2D and incident HF in Canada, sitagliptin use was associated
with an increased risk of HHF only among patients with pre-
existing HF.9 Finally, Velez et al.29 reported that, among 4224 pa-
tients with T2D treated with an incretin- or non-incretin-based
regimen (1 : 2 ratio), the use of DPP-4i was associated with a sig-
nificantly lower risk of HHF, all-cause hospitalization, and
mortality.
In addition to these observational data, three meta-analyses of
phase III – IV randomized-controlled trials, including 55 141–85
224 patients, reported an increased risk of HHF from 16 to 19% as-
sociated with the use of DPP-4i.10– 12 However, the increased risk of
HHF was mainly driven by the SAVOR trial, which was the largest
and longest study included in the aforementioned meta-analyses.
Uncertainty remains on the concerns raised by the SAVOR study
regarding the risk of HF associated with DPP-4i therapy vs. placebo,
but the question raises on the comparative effect of DPP-4i vs. other
second-line oral agents for T2D. In this very large observational
study, we specifically focused on the comparison between DPP-4i
and sulphonylureas, which are still the most used oral medications
for the treatment of T2D in Italy. In order to limit selection bias, we
purportedly excluded patients on diet alone or on metformin
monotherapy, as they would be predicted to be healthier, with
shorter disease duration and lower HbA1c than patients who
received treatment intensification with a second-line oral agent
(sulphonylurea, TZD, or DPP-4i). The 28–30% lower risk of HHF
detected in the DPP-4i group may thus derive from a beneficial pro-
tective effect of DPP-4i or from a detrimental effect of sulphonylur-
eas on HF. In fact, sulphonylureas have been associated with an
increased risk of HF compared with metformin.30 – 32 In any case,
our findings may have implications for the care of T2D in routine
clinical practice and may favour a shift in prescription trends towards
oral medications, with a more favourable cardiovascular risk profile.
We also show that use of glitazones was not associated with
excess HHF, likely because clinicians aware of the potential
HF-precipitating effect of glitazones do not prescribe such drugs
to patients deemed at risk.
Our study has limitations inherent to its observational and retro-
spective nature. The typical bias is that differences in the outcomes
according to ongoing therapies may not be attributable to specific
effects of the drugs, but rather to the reasons whereby different
patients receive different drugs. This is clearly demonstrated by
the statistically significant and clinically meaningful differences in
baseline characteristics, according to the glucose-lowering medica-
tion regimen (Table 1). Despite multivariable adjusting, residual bias
is typically generated from unmeasured confounders. For instance,
we have no data on body mass index, glucose control, disease dur-
ation, microvascular complications, and asymptomatic left ventricu-
lar dysfunction, all of which may affect the risk of HF. In addition,
prescription of DPP-4i is subjected to a registry-based appropriate-
ness evaluation and monitoring in Italy, thereby increasing the
Figure 2 Kaplan–Meier curves showing HHF-free survival in
the three groups of patients on DPP-4 inhibitors (DPP-4i), glita-
zones, or sulphonylureas in matched samples. Owing to the low
absolute rate of HHF, curves are indistinguishable when the
Y-axis is set from 0 to 1. The plot has been therefore exploded
in the insert graph with Y-axis set from 0.95 to 1.00.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Results of the Cox proportional hazard multiple regression analysis in the whole study population including
hospitalization episodes with a primary or secondary HF diagnosis
Variable Before propensity matching After propensity matching
HR (95% CI) P-value HR (95% CI) P-value
Glucose-lowering medications
Sulphonylureas (reference) 1.000 1.000
Glitazones 0.926 (0.807–1.063) 0.277 0.777 (0.635–0.950) 0.014
DPP-4 inhibitors 0.751 (0.630–0.895) 0.001 0.642 (0.510–0.808) ,0.001
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likelihood that patients on DPP-4i were prescribed the drugs more
appropriately and followed-up more regularly in a specialty settings
than those prescribed other medications. To improve reliability and
cope with selection and prescription biases, the propensity score
matching provides a means of reducing the differences among
patient groups by accounting for the covariates that predict receiv-
ing the treatment.33 After matching, the study cohort was reduced
to 39 465 patients, and use of DPP-4i was still associated with a sig-
nificantly lower risk of HHF. These results strongly reinforce what
was shown in the total population using multivariate adjustment.
In addition, use of DPP-4i was associated with a lower HR risk
than use of sulphonylureas, even when including hospitalization
with both primary and secondary diagnoses of HF.
In the sensitivity analysis, the use of DPP-4i was associated with an
increased risk of HHF compared with sulphonylureas in patients
with less than 6 months of follow-up. This analysis does not allow
proper adjustment for adherence to medications, which is critical
when exposure is determined by prescription records, thereby
generating uncertainties on whether the patients actually took
the drugs. The results may be also explained by reverse causality,
i.e. a higher likelihood of being prescribed a DPP-4i than a sulphony-
lurea in patients deemed at risk for HHF in the short term. In fact,
when the analysis included patients with a previous history of HF,
those in which the risk of subsequent HF is highest, the use of
DPP-4i still showed trend protection against HHF.
In conclusion, this large observational study shows lower HHF
risk in DPP-4i- vs. sulphonylurea-treated patients. These data do
not confirm, nor contrast with what was shown by the SAVOR trial,
which only compared saxagliptin with placebo. While waiting for the
forthcoming phase IV randomized comparator-controlled trials on
cardiovascular outcomes of DPP-4i, this reassuring finding may
provide a basis for guiding the clinical care of patients with T2D.
Supplementary material
Supplementary material is available at European Heart Journal online.
Authors’ contributions
All authors contributed substantially to study conception and de-
sign, acquisition of data, analysis and interpretation of data, drafting
the article, or revising it critically. All authors approved the final ver-
sion to be published. The views presented in this article are those of
the authors and should not be understood or quoted as being made
on behalf of the Italian Medicines Agency (AIFA) and/or the Euro-
pean Medicines Agency (EMA) and/or their scientific committees.
Acknowledgements
Composition of the OsMed Health-DB Network: Azienda Sanitaria
Locale di Asti (Piemonte): S. Martinetti, P. Mero, L. Raeli; ASL Pavia
(Lombardia): S. Migliazza, M. Dellagiovanna, C. Cerra; Azienda Sani-
taria Locale della Provincia Bergamo (Lombardia): M. Gambera,
R. Piccinelli, M. Zambetti, F. Atzeni; Azienda Sanitaria Locale della
Provincia di Lecco (Lombardia): V. Valsecchi, P. DeLuca,
E. Scopinaro, D. Moltoni; Azienda Sanitaria Locale della Provincia
di Varese (Lombardia): E. Pini, O. Leoni, C. Oria, M. Papagni,
G. Nosetti, E. Caldiroli; Azienda Sanitaria dell’Alto Adige (Trentino-
Alto Adige): V. Moser; Azienda Provinciale per i Servizi Sanitari—
Provincia Autonoma di Trento (Trentino-Alto Adige): R. Roni,
A. Polverino; Azienda ULSS20 di Verona (Veneto): C. Bovo,
L. Mezzalira, M. Andretta, L. Trentin; Azienda per Servizi Sanitari
n. 1 Triestina (Friuli Venezia Giulia): S. Palcic, A. Pettinelli; Azienda
per Servizi Sanitari n. 2 Isontina (Friuli Venezia Giulia): A. Arbo,
A. Bertola, G. Capparoni; Azienda per i Servizi Sanitari n. 4 Medio
Friuli (Friuli Venezia Giulia): C. Cattaruzzi, L. Marcuzzo; Azienda
per Servizi Sanitari n. 6 Friuli Occidentale (Friuli Venezia Giulia):
F.V. Rosa, B. Basso; Azienda USL No. 1 Imperiese (Liguria):
M. Saglietto, S. Delucis, M. Prioli, R. Filippi; ASL n. 3 Genovese
(Liguria): A. Coccini, M. Ghia, F. Sanfelici; Azienda Unità Sanitaria
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